The liver is central to the maintenance of glucose and lipid homeostasis, and liver X receptors (LXRs) are key regulators of expression of the genes involved. So far, effects of activation of LXR in human hepatocytes have not been well characterized. Here we show that treatment of primary human hepatocytes with the synthetic LXR ligand 3-[3-[N-(2-chloro-3-trifluoromethylbenzyl)-(2,2-diphenylethyl)amino]propyloxy]phenylacetic acid hydrochloride (GW3965) results in reduced output of bile acids and very low density lipoprotein triglycerides and induced expression of adipose differentiation-related protein accompanied by increased lipid storage. Genome wide-expression profiling identified novel human LXR target genes in the glycolytic and lipogenic pathways and indicated that LXR activation reduced hepatic insulin sensitivity. Comparative experiments showed significant differences in the response to GW3965 between human and rat hepatocytes, raising the question as to how well rodent models reflect the human situation. In summary, the risk of hepatic steatosis upon pharmaceutical targeting of LXR may be a particularly serious consequence in humans.When adaptive physiological strategies to cope with surplus energy become exceeded, associated pathogeneses such as glucose intolerance, insulin resistance, and dyslipidemia develop. Members of the nuclear receptor family have emerged as key metabolic sensors regulating the expression of genes involved in intermediary metabolism (Francis et al., 2003;Shulman and Mangelsdorf, 2005) and LXR␣ and LXR, acting as cholesterol sensors, are considered to be potential drug targets for the alleviation of symptoms of metabolic diseases (Zelcer and Tontonoz, 2006).In rodents but not in humans, LXR activation enhances hepatic cholesterol catabolism partly through increased expression of cytochrome P450 7A1, the rate-limiting enzyme in the classic conversion of cholesterol to bile acids (Chiang et al., 2001). Moreover, it has been shown that LXR agonists